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Abstract
The galactosaminogalactan (GAG) is a cell wall component of Aspergillus fumigatus that has potent anti-inflammatory effects
in mice. However, the mechanisms responsible for the anti-inflammatory property of GAG remain to be elucidated. In the
present study we used in vitro PBMC stimulation assays to demonstrate, that GAG inhibits proinflammatory T-helper (Th)1
and Th17 cytokine production in human PBMCs by inducing Interleukin-1 receptor antagonist (IL-1Ra), a potent anti-
inflammatory cytokine that blocks IL-1 signalling. GAG cannot suppress human T-helper cytokine production in the
presence of neutralizing antibodies against IL-1Ra. In a mouse model of invasive aspergillosis, GAG induces IL-1Ra in vivo,
and the increased susceptibility to invasive aspergillosis in the presence of GAG in wild type mice is not observed in mice
deficient for IL-1Ra. Additionally, we demonstrate that the capacity of GAG to induce IL-1Ra could also be used for
treatment of inflammatory diseases, as GAG was able to reduce severity of an experimental model of allergic aspergillosis,
and in a murine DSS-induced colitis model. In the setting of invasive aspergillosis, GAG has a significant immunomodulatory
function by inducing IL-1Ra and notably IL-1Ra knockout mice are completely protected to invasive pulmonary aspergillosis.
This opens new treatment strategies that target IL-1Ra in the setting of acute invasive fungal infection. However, the
observation that GAG can also protect mice from allergy and colitis makes GAG or a derivative structure of GAG a potential
treatment compound for IL-1 driven inflammatory diseases.
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Introduction
Aspergillus fumigatus is an opportunistic fungus that causes
infections under specific conditions, of which secondary immuno-
deficiency is by far the largest risk factor for the development of
invasive infections [1]. In order to initiate an effective host
response against Aspergillus, recognition of conserved pathogen
associated molecular patterns (PAMPs) by specific pattern
recognition receptors (PRRs) is required.
A. fumigatus has a complex cell wall consisting of polysaccha-
rides that play essential biological functions in fungal cell biology
and host-pathogen interactions. Some of these polysaccharides
are recognized by various PRRs expressed on human immune
cells [2]. However, A. fumigatus employs various strategies to
evade immune recognition. Aspergillus expresses surface molecules
that shield PAMPs or can modulate TLR responses [3]. Several
surface molecules and PAMPs of A. fumigatus have been
characterized as being capable of modulating or suppressing
the immune response. Rodlets and melanin, that are present on
the conidial surface, shield PAMPs that elicit pro-inflammatory
host responses [4,5]. In addition, b-glucan, a-glucan and
galactomannan (GM) have been shown to modulate the host
immune response [6].
Another cell wall component of A. fumigatus that is capable of
modulating the immune response is galactosaminogalactan
(GAG) [7]. GAG is not expressed on Aspergillus conidia, but is
exposed when conidia start to germinate and was found to be
present in the extracellular matrix that surrounds Aspergillus
hyphae in aspergilloma isolated from patients and in experi-
mental murine invasive aspergillosis [8]. Furthermore, GAG
has been shown to serve as an adhesin of Aspergillus [9,10] and
to shield b-glucan moieties on the cell wall [9]. This
polysaccharide that is shed into the host environment during
Aspergillus vegetative growth induces immunosuppressive effects
PLOS Pathogens | www.plospathogens.org 1 March 2014 | Volume 10 | Issue 3 | e1003936
that results in diminished neutrophil recruitment, which
predisposes mice to A. fumigatus infection [7]. However, the
mechanism through which GAG induces immunosuppressive
effects as well as its capacity to induce similar immunosup-
pressive effects on the human immune response were unknown.
Therefore, we investigated whether GAG can be immunosup-
pressive in the human host response against A. fumigatus, and we
have systematically addressed the possible mechanisms respon-
sible for the anti-inflammatory property of GAG.
Results
Galactosaminogalactan modulates human T-helper
cytokine responses
To investigate whether GAG can exert immunomodulatory
effects in humans, we tested whether GAG induces the production
of pro- and/or anti-inflammatory cytokines in human PBMCs.
GAG did not induce the proinflammatory cytokines TNFa, IL-6,
IL-8, IFN-c, IL-17, IL-5 and IL-9 (Figure 1A), neither did it
induce the anti-inflammatory cytokine IL-10 (Figure 1A). To
determine whether GAG modulates Aspergillus-induced innate
monocyte-derived cytokines, PBMCs were stimulated for 24 hours
with Aspergillus conidia (these morphotypes of A. fumigatus were
selected because they do not contain GAG that would interfere
with the study of the immunological function of GAG) in the
presence or absence of GAG. The presence of GAG did not have
a significant effect on the production of the innate cytokines TNFa
and IL-6, or the anti-inflammatory cytokine IL-10 (Figure 1B).
However, when the production of the characteristic T-helper
cytokines IL-17, IL-22 and IFN-c induced by A. fumigatus was
investigated, the IL-17 and IL-22 responses were significantly
reduced in the presence of GAG (Figure 1C). To determine
whether the effects of GAG are specific for Aspergillus-driven T-
helper (Th) responses, or whether GAG has a general ability to
modulate human Th responses, the effects of GAG on cytokine-
driven Th responses were studied. GAG significantly decreased
the proinflammatory Th cytokine production induced by the
cytokine combinations IL-1b/IL-23 and IL-12/IL-18 that induce
IL-17/IL-22 and IFN-c, respectively (Figure 1E). Thus, GAG can
inhibit human proinflammatory Th cytokine production induced
by Aspergillus and cytokine cocktails.
Galactosaminogalactan induces IL-1 receptor antagonist
Human Th cytokine responses such as IL-17 and IL-22
production are highly dependent on the IL-1 receptor pathway
[11,12]. To investigate whether the observed modulation of Th
cytokines by GAG was due to an interaction of GAG with the IL-1
pathway, we determined the capacity of GAG conditioned
medium (culture supernatants of PBMCs that were exposed to
10 mg/ml GAG for 24 hours) to reduce IL-1b bioactivity. Indeed
it was shown that GAG significantly reduced the bioactivity of IL-
1b while culture supernatants of unstimulated PBMCs did not
(Figure 2A). Bioactivity of the IL-1 signalling pathway is
dependent on IL-1 receptor agonists (IL-1a and IL-1b) and IL-1
receptor antagonists [13]. One of the natural inhibitors of the IL-1
signalling is the interleukin-1 receptor antagonist (IL-1Ra);
therefore the ability of GAG to induce IL-1Ra was tested. IL-
1Ra concentrations in the supernatant of the cells stimulated with
GAG were significantly increased, whereas GAG induced none of
the IL-1 receptor agonists, IL-1a or IL-1b (Figure 2B), showing
that GAG has the capacity to modulate immune responses by
blocking the IL-1 receptor pathway.
Suppression of IL-17 and IL-22 by galactosaminogalactan
is dependent on IL-1Ra
To demonstrate that IL-17, IL-22, and IFN-c production by
human PBMCs is indeed dependent on the IL-1 receptor pathway
and that IL-1Ra can inhibit the production of these Th cytokines,
Th1 and Th17 inducing stimuli were studied in the presence or
absence of IL-1Ra. Addition of IL-1Ra reduced IL-17, IL-22, and
IFN-c induction by both Aspergillus conidia and by IL-1/IL-23 and
IL-12/IL-18 cytokine combinations (Figure 3A). To determine
whether the immunosuppressive effect of GAG was mediated
through the induction of IL-1Ra, PBMCs were stimulated with IL-
1b/IL-23 and GAG in the presence or absence of neutralizing
anti-IL-1Ra antibodies. GAG reduced IL-17 and IL-22 levels
significantly, which was not observed in the presence of
neutralizing anti-IL-1Ra antibodies, demonstrating that the
inhibitory effects of GAG on Th cytokine production are
dependent on IL-1Ra (Figure 3B).
Galactosaminogalactan induces IL-1Ra in vivo and IL-1Ra
increases susceptibility to aspergillosis
The in vitro stimulations described above suggest that the
immunomodulatory effects of GAG are due to inhibition of IL-1
bioactivity by inducing IL-1Ra. To assess whether this has relevant
consequences in vivo, we measured IL-1Ra transcription in the
lungs of mice infected with Aspergillus with or without the
administration of GAG. Induction of Il1ra was increased in the
presence of GAG (Figure 4A). To determine which cells are
responsible for the induction of Il1ra, we isolated macrophages,
neutrophils and epithelial cells from the lungs of naı¨ve mice.
Macrophages and neutrophils, but not epithelial cells, expressed
Il1ra after stimulation with Aspergillus in the presence of GAG
(Figure 4B). Interestingly, not all microbiological stimuli can prime
for increased GAG-induced Il1ra, since pre-stimulation with LPS
did not increase Il1ra induction by GAG (Figure 4B).
To investigate the significance of IL-1Ra in vivo and to
determine whether the effects induced by GAG are dependent
on IL-1Ra, we studied the effects of GAG in wild type (WT) and
Il1ra2/2 mice with invasive aspergillosis. Il1ra2/2 mice were
Author Summary
Aspergillus fumigatus is an opportunistic pathogenic
fungus that primarily causes infections in the immuno-
compromised host. It is known that Aspergillus employs
various strategies to evade immune recognition by the
host’s immune system. Recently, galactosaminogalactan
(GAG), a new component of the Aspergillus cell wall, was
discovered to have potent anti-inflammatory effects in
mice making them more susceptible to Aspergillosis. In the
current study we found that this anti-inflammatory
property of GAG was due to its capacity to induce the
potent anti-inflammatory cytokine interleukin-1 Receptor
antagonist. This cytokine interferes with IL-1 signalling and
thereby can reduce IL-1–induced immune responses such
as T-cell responses. We also found that the induction of
this anti-inflammatory cytokine by GAG correlates with
increased fungal burden, and mice deficient for this
cytokine were protected against aspergillosis. Additionally,
we show that the capacity of GAG to induce the natural
regulator of IL-1 signalling could be used in the treatment
of IL-1–mediated disease such as allergy and colitis. Our
study provides new insights on the immunoregulatory
activity of GAG and opens up possibilities to exploit the
anti-inflammatory potential of GAG as a therapy for
inflammatory diseases.
GAG of Aspergillus fumigatus Induces IL-1Ra
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Figure 1. GAG inhibits Aspergillus-induced human T-helper cell cytokine production. (A) TNFa, IL-6, IL-8 and IL-10 concentrations in culture
supernatants of human PBMCs stimulated for 24 hours with 10 mg/ml GAG and IFN-c, IL-17, IL-5 and IL-9 concentrations after 7 days of stimulation.
(B) TNFa, IL-6 and IL-10 concentrations in culture supernatants of human PBMCs (n = 6 donors) stimulated for 24 hours with heat inactivated A.
fumigatus conidia (16107/ml) in the presence or absence of 10 mg/ml GAG. (C,D) IL-17, IL-22 and IFN-c concentrations in culture supernatants of
human PBMCs stimulated for 7 days with heat inactivated A. fumigatus conidia (16107/ml) (n = 10 donors for IL-17 and IL-22, n = 6 donors for IFN-c)
(c), IL-1b/IL-23 (50/100 ng/ml) (n = 14 donors) or IL-12/IL-18 (50/100 ng/ml) (n = 10 donors) in the presence or absence of GAG (10 mg/ml). Data are
represented as mean +/2 SEM.
doi:10.1371/journal.ppat.1003936.g001
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highly resistant to invasive aspergillosis, as indicated by long-term
survival (Figure 4C) and reduced fungal burden (Figure 4D).
Administration of GAG resulted in increased protein levels of IL-
1Ra in the lungs of wild-type mice during infection (Figure 4E). In
line with previous observations, GAG increased the susceptibility
to invasive aspergillosis in WT mice but not in Il1ra2/2 mice
(Figure 4D). Il1ra2/2 mice had increased Mpo expression
(Figure 4F) and PMN influx in their respiratory tract (Fig. 4G).
As expected, administration of GAG reduced inflammatory PMN
recruitment in WT but not in Il1ra2/2 mice (Figure 4G). These
data demonstrate that IL-1Ra has an important role in invasive
aspergillosis, and support the concept that the induction of IL-1Ra
by GAG may have important clinical consequences.
In ABPA, GAG administration decreased PMN recruitment,
but not eosinophilic infiltration in the BAL and lung of allergic
mice (Figure 4H), a finding consistent with decreased Th17 but
not Th2 cell responses in the draining lymph nodes (Figure 4I). To
address whether GAG would have similar effects on human Th2
responses, PBMCs isolated form healthy subjects were pre-
incubated for 1 h with GAG and subsequently stimulated with
Aspergillus conidia for 7 days. Similar to mice, IL-17 production
decreased in the presence of GAG, but not Th2 cytokines such as
IL-5 and IL-13 (Figure 4J). Thus, GAG has the potential to
ameliorate Th17-dependent immunopathology in ABPA.
IL-1Ra induction by Galactosaminogalactan can be
exploited as a therapy for IL-1–mediated inflammatory
diseases
Since IL-1Ra treatment can be beneficial for autoinflammatory
diseases such as chronic granulomatous disease CGD colitis in
humans [14], we investigated whether GAG could be beneficial in
experimental DSS-induced colitis in mice with chronic granulo-
matous disease (CGD). The administration of GAG resulted in the
amelioration of clinical signs of colitis (weight loss and stool
consistency) (Figure 5A-B) and of inflammatory lesions (Figure 5C)
in both wild-type and CGD mice. However the protective effects
of GAG were most apparent in CGD mice. GAG induced IL-1Ra
and, consistently, reduced IL-1b and IL-17 (Figure 5D). Concom-
itantly, there was an increased production of IL-10, an anti-
inflammatory cytokine that plays an important role in the
protection of colitis [15,16]. The effects of GAG on CGD colitis
were similar to those of IL-1Ra administration (unpublished data).
Discussion
In the original report describing GAG [7], it was shown that
GAG has anti-inflammatory effects in mice. However, the
mechanism through which GAG elicits its immunomodulatory
effects remained a question at that time. In the present study, we
demonstrate that GAG induces its anti-inflammatory effects by
inducing the potent anti-inflammatory cytokine IL-1 receptor
antagonist.
IL-1Ra can inhibit the activation of the IL-1 pathway by
binding to the IL-1R type 1 receptor and prevents recruitment of
the IL-1R accessory protein that is required for signalling. It has
been repeatedly shown that IL-1 is an essential proinflammatory
cytokine of the innate immunity. A deficient IL-1 pathway is also
detrimental for the host, since it is an important protective
pathway required to fight infection [17]. Thus the IL-1 axis is a
potent pro-inflammatory pathway that needs to be tightly
regulated, and IL-1Ra is a crucial player in this regulation.
Therefore, it is rather surprising that the role of IL-1Ra in invasive
fungal infection has not been studied in detail to date. We
observed that the absence of IL-1Ra completely protects mice
from developing invasive pulmonary aspergillosis, underscoring
the importance of the IL-1 pathway in clearance of an acute
invasive Aspergillus infection. The observation that GAG induces
IL-1Ra in vivo identifies GAG as a potent anti-inflammatory
molecule that suppresses the IL-1 pathway, subsequently resulting
in increased susceptibility to invasive aspergillosis. The relevance
of the IL-1 pathway in aspergillosis is underscored by the fact that
polymorphisms IL-1 gene cluster polymorphisms are associated
with susceptibility to develop in invasive pulmonary aspergillosis
[18], and that dectin-1 knockout mice display increased fungal
burden and mortality during invasive aspergillosis, which is
dependent on IL-1 [19].
One of the major risk factors that increases susceptibility to
invasive aspergillosis is neutropenia [20], and neutrophils are
crucial for clearing invasive germinating and hyphal forms of
Aspergillus infection [21]. GAG has been shown to inhibit
neutrophil recruitment to the lung, which is at least partly due
Figure 2. GAG induces interleukin 1 receptor antagonist. (A) IL-1 bioactivity measured as IL-2 production by NOB-1 cells stimulated with
50 ng/ml IL-1b in the presence of culture supernatant of unstimulated PBMCs (medium) or culture supernatants of PBMCs that were exposed to
10 mg/ml GAG for 24 hours (GAG conditioned medium) (n = 6 donors). (B) IL-1Ra, IL-1b and IL-1a concentrations in culture supernatants of human
PBMCs stimulated with for 24 hours with 10 mg/ml GAG. Data are represented as mean +/2 SEM.
doi:10.1371/journal.ppat.1003936.g002
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to neutrophil apoptosis [7]. We observed that in the presence of
GAG, IL-1Ra increased during invasive aspergillosis, which
correlated with decreased PMN recruitment, and therefore
increased fungal burden. In contrast, Il1ra2/2 mice displayed
increased neutrophil influx when exposed to Aspergillus, which
could explain the resistance of Il1ra2/2 mice to invasive
aspergillosis, since they can rapidly and efficiently clear Aspergillus
conidia due to their increased neutrophil response. In addition to
the induction of IL-1Ra by GAG in vitro and in vivo, we observed
that the inhibitory effects of GAG on the proinflammatory Th
cytokine response in human PBMCs could be restored in the
presence of a neutralizing antibody against human IL-1Ra.
Furthermore, the increased susceptibility to invasive aspergillosis
induced by GAG is not observed in Il1ra2/2 mice. These
observations strengthen the hypothesis that the anti-inflammatory
properties of GAG are dependent on IL-1Ra.
The anti-inflammatory properties of GAG were present at a
concentration of 10 mg/ml, which is a relevant concentration in
vivo, since Aspergillus can secrete GAG in a concentration of 50 mg/
ml (data not shown). The finding that antibodies against GAG are
present in human serum [8] suggests that there is an adequate
exposure of GAG to trigger the immune system. In the present
study we were also able to demonstrate that these antibodies do
not inhibit the effect of GAG, since we observed significant effects
of GAG on IL-1Ra induction and inhibition of IL-17 in the
presence of human serum that contained measurable concentra-
tions of antibodies against GAG (data not shown). The relevance
of GAG is highlighted by its presence in the extracellular matrix in
aspergilloma resected from patients and mice with aspergillosis [8].
It is therefore expected that GAG plays a role in the immuno-
logical synapse between host immune cell and the mycelium, not
only by inducing anti-inflammatory responses through IL-1Ra but
Figure 3. Suppression of IL-17 and IL-22 by GAG is dependent on IL-1Ra. (A) IL-17, IL-22 and IFN-c concentrations in culture supernatants of
PBMCs stimulated for 7 days with heat inactivated A. fumigatus conidia 16107/ml, IL-1b/IL-23 (50/100 ng/ml) or IL-12/IL-18 (50/100 ng/ml) in the
presence or absence of recombinant human IL-1Ra (10 ng/ml). Data are represented as mean +/2 SEM. (B) Inhibition of IL-1b/IL-23 (50/100 ng/ml)
induced IL-17 and IL-22 by GAG (10 mg/ml) in human PBMCs in the presence of isotype control (10 mg/ml) or anti-IL-1Ra (10 mg/ml). The IL-17 and IL-
22 production by IL-1b/IL-23 in absence of GAG was set at 100% and mean percentage changes relative to the control are represented +/2 SEM.
doi:10.1371/journal.ppat.1003936.g003
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also by shielding b-glucan from recognition, which has been
proposed previously [9].
It must be taken into account that in the setting of chronic
inflammation in which neutrophils and increased Th17 responses
are detrimental for the host, IL-1Ra plays a protective role, due to
its significant capability to suppress the IL-1 signaling pathway.
This hypothesis is in line with the observation that Il1ra2/2 mice
develop spontaneous destructive arthritis that is IL-1 and Th17
Figure 4. GAG induces IL-1Ra in vivo and IL-1Ra increases susceptibility to aspergillosis. BALB/c and Il1ra2/2 mice were intranasally
infected with Aspergillus conidia and treated with GAG (250 mg/kg intranasally) the day of infection, and 1, 2 and 3 days post-infection. (A) Il1ra mRNA
expression in lung homogenates of mice with invasive aspergillosis, (B) Il1ra mRNA expression in purified cells from lungs of naive mice pre-
stimulated with Aspergillus conidia or LPS for 1 hour, and exposed to different GAG concentrations for an additional 18 hours. (C) Survival, (D) fungal
growth (CFU/lung, mean +/2SEM), (E) protein levels of IL-1Ra, (F) Mpo expression in lung homogenates, and (G) BAL morphometry [%
polymorphonuclear (PMNs) cells and lung histology (PAS stained sections, bars indicate 206magnification) of Aspergillus-infected mice with or
without GAG treatment. Assays were done a day after the last GAG treatment. (H) BAL morphometry [% PMNs or eosinophils (Eo)] and lung histology
(PAS stained sections, bars indicate 206magnification), and (I) expression of Th transcription factors and cytokines in total cells from the draining
lymph nodes in mice with ABPA and treated with or without GAG. Naı¨ve means uninfected mice, and none means untreated mice and/or
unstimulated cells. (J) IL-5, IL-13 and IL-17 concentrations in culture supernatants of PBMCs pre-incubated 1 h either with medium or GAG (10 mg/ml).
After washing, the cells were stimulated for 7 days with heat inactivated 16107/ml A. fumigatus conidia (n = 4 donors). Data are represented as mean
+/2 SEM. *, p,0.05; **, p,0.01.
doi:10.1371/journal.ppat.1003936.g004
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dependent [22]. The importance of IL-1Ra in controlling IL-1
mediated proinflammatory responses in humans is underlined by a
disease called deficiency of IL-1Ra (DIRA). This disease is
characterized by the absence of IL-1Ra and severe Th17 mediated
responses with neutrophil influx in the skin and bones of these
patients, subsequently resulting in severe skin inflammation and
osteomyelitis [23]. Therefore, the timing of IL-1Ra induction is of
utmost importance to protect the host from infection and
overwhelming inflammation. Chronic allergic aspergillosis is
associated with excessive inflammation, with increased production
of IL-1 and IL-22 [24]. We have demonstrated in the present
study that administration of GAG induces IL-1Ra and is able to
decrease IL-22 production. Therefore we investigated the effect of
GAG in a murine model of allergic bronchopulmonary aspergil-
losis (ABPA). We observed that the administration of GAG
reduces the amount of neutrophils, but not eosinophils in ABPA.
Additionally, Th17 responses were downregulated, but not Th2
responses. It is therefore tempting to speculate that administra-
tion of GAG can be beneficial in the setting of chronic allergic
inflammation that is associated with excessive neutrophil-driven
inflammation by reducing Th17 dependent pathology by
inhibiting the IL-1 pathway. In addition, GAG also protected
CGD mice from experimental colitis. Therefore, we envisage a
model in which GAG on the one hand might be detrimental for
the host in the setting of an acute infection, and on the other
hand could be beneficial for the host during chronic inflamma-
tion driven by IL-1. Next to the identification of GAG or IL-1Ra
as a therapeutic target for invasive aspergillosis, it is the first time
that a polysaccharide produced by a human pathogen has been
identified as an inducer of IL-1Ra by cells of the innate immunity
without inducing proinflammatory responses, and which has been
demonstrated to have therapeutic capacity in IL-1 mediated
disease. The search of the sensing and signal transduction cascade
activated by this polysaccharide will now be the center of future
research.
The data presented here brings new questions into light and
opens opportunities for future research. First, one of the most
interesting observations is the complete protection of IL-1Ra
knockout mice to invasive pulmonary aspergillosis. This opens new
treatment strategies that target IL-1Ra in the setting of an acute
invasive fungal infection. Second, the significant induction of IL-
1Ra by GAG makes GAG or a derivative structure of GAG a
Figure 5. GAG protects mice from experimental DSS-induced colitis. (A) Body weight losses, (B) stool and histological score, (C) histology of
colonic sections and (D) cytokine concentrations present in total colonic cells a day after the 7-day of DSS rest in C57BL/6 and p47phox2/2 (CGD) mice
with or without GAG treatment. *P,0.05, GAG treated vs. untreated mice.
doi:10.1371/journal.ppat.1003936.g005
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potential treatment compound for IL-1–mediated diseases, such as
joint, bone and muscle diseases and even very common
inflammatory diseases such as diabetes and gout [25]. Previously,
we have shown that mitogenic stimulation of monocyte derived
macrophages and lymphocytes by aCD3/aCD28 coated beads, or
recombinant cytokine-induced IL-17 and IFN-c production is
inhibited in the presence of live A. fumigatus [26]. Although these
changes in cytokine responses were attributed to changes in
tryptophan and kynurenine, it is tempting to speculate that GAG
secretion by live A. fumigatus could have attributed to the decreased
IL-17 production.
In conclusion, our results demonstrate that GAG has potent
anti-inflammatory effects in mice and humans that can be
explained by the capability of GAG to induce IL-1Ra. These
observations help to explain one of the immune-evasive mecha-
nisms of A. fumigatus. Moreover, inhibition of GAG or IL-1Ra
might prove beneficial in the treatment of acute invasive
pulmonary aspergillosis, and GAG might be exploited for
treatment of IL-1–mediated inflammatory diseases.
Materials and Methods
Ethics statement
All studies with human blood samples were conducted in the
Radboud University Nijmegen Medical Centre and the use of
healthy volunteers was approved by the institutional ethics
review board. Peripheral venous blood samples from healthy
volunteers were obtained after written informed consent was
provided.
All animal studies were conducted within the University of
Perugia and were performed according to the Italian Approved
Animal Welfare Assurance A–3143–01. Legislative decree 245/
2011-B regarding the animal license was obtained by the Italian
Ministry of Health lasting for three years (2011–2014). Infections
were performed under avertin anesthesia and all efforts were made
to minimize suffering.
Galactosaminogalactan
Galactosaminogalactan (GAG) was isolated from A. fumigatus
culture supernatant and purified from the urea-soluble fraction as
previously described [7]. Lyophilized GAG was resuspended in
10 mM HCl at 2 mg/ml and used in a final concentration of
10 mg/ml. Before using GAG in stimulation experiments it was
incubated with polymixin B to neutralize potential contamination
of lipopolysaccharide.
Stimuli and reagents
A clinical isolate of Aspergillus fumigatus V05-27, which has been
previously characterized was used for stimulations [27]. Conidia
and hyphae were prepared and heat-killed as previously described
[6]. A concentration of 16107/ml was used in the experiments,
unless otherwise indicated. Recombinant human IL-1b, IL-23, IL-
12 and IL-18 were purchased from R&D Systems (Minneapolis,
MN, USA) and were used in end concentrations of 100 ng/ml,
50 ng/ml, 10 ng/ml and 50 ng/ml respectively. Recombinant
human (rh) IL-1Ra (Amgen, Inc., Thousand Oaks, CA, USA) was
used to antagonize IL-1b signalling at a final concentration of
10 ng/ml. Anti-humanIL-1Ra (R&D) was used to block IL-1Ra in
a final concentration of 10 mg/ml, and was compared to isotype
control.
PBMC isolation and stimulation
PBMCs were isolated as described previously [28]. The cells
were counted using a particle counter (Beckmann Coulter,
Woerden, The Netherlands) and the cell number was adjusted
to 56106/ml. PBMCs were plated in 96-well round-bottom
plates (Corning, NY, USA) at a final concentration of 2,56106/
ml and in a total volume of 200 ml. Cells were pre-stimulated for
1 hour with medium or 10 mg/ml GAG. Following prestimula-
tion, the PBMCs were stimulated with culture medium, heat
killed A. fumigatus conidia (16107/ml), IL-1b/IL-23 (100 and
50 ng/ml respectively) or IL-12/IL-18 (10 and 50 ng/ml
respectively). These experiments were also performed in the
presence of 10 mg/ml anti-IL-1Ra antibody or isotype control.
Plates were incubated at 37uC, 5% CO2 for 24 hours, 48 hours
or 7 days. 7 day cultures were supplemented with 10% human
serum. In this serum we detected anti-GAG antibodies as
described previously [7]. After incubation, culture supernatants
were collected and stored at -20uC until cytokine measurements
were performed.
IL-1 bioassay
The murine cell line NOB-1 responds to both human or mouse
IL-1 by production of IL-2, furthermore these cells are unrespon-
sive to other cytokines like tumor necrosis factor (TNF), colony
stimulating factors (CSFS), IL-3, IL-5, IL-6 and IFN-c [29]. NOB-
1 cells were plated in 96 well flat-bottom plates at a final density of
16106 cells/ml and were stimulated for 24 hour using culture
supernatants of unstimulated PBMCs or PBMCs stimulated in
presence of GAG (GAG conditioned medium). After 24 hours of
incubation at 37uC, 5% CO2 the culture supernatants of the
NOB-1 cells were collected and IL-2 production by the NOB-1
cells was measured by ELISA (R&D systems).
Cytokine measurement
Cytokines were measured using commercially available ELISAs
(R&D Systems)(Biolegend, San Diego, CA, USA) (Sanquin,
Amsterdam, The Netherlands) according to the protocols supplied
by the manufacturer. IL-1a, IL-1b, TNF-a, IL-6, IL-8, IL-1Ra
and IL-10 were measured in culture supernatants of 24 hour
cultures, and IL-5, IL-9, IL-13, IL-17, IL-22 and IFN-c were
measured in culture supernatants of 7 day cultures.
Mice
Female, 8- to 10-weeks old, BALB/c (wild-type, WT) mice were
purchased from Charles River (Calco, Italy). Breeding pairs of
homozygous Il1ra2/2mice on the BALB/c background, were kept
under specific-pathogen free conditions at the breeding facilities of
the University of Perugia, Perugia, Italy. Experiments were
performed according to the Italian Approved Animal Welfare
Assurance 229-2011-B.
Fungal infection, allergy and treatment
Viable conidia from the A. fumigatus Af293 strain were obtained
as described [30]. For infection mice were anesthetized in a small
plastic cage, containing 3% Isofluoran (Isofluran Forene Abbot
Scandinavia AB, Solna) before intranasal (i.n.) instillation of a
suspension of 26107 resting conidia/20 ml saline. Mice were
treated with 250 mg/kg i.n. of GAG the day of infection and on
days 1 to 3 post infection. Mice were monitored for survival, fungal
growth (colony forming unit/organ, mean 6 SEM), as described
[31], histopathology, myeloperoxidase (Mpo) and Il1ra mRNA
expression in lung cells and IL-1Ra production. For histology,
sections (3–4 ı`m) of paraffin-embedded tissues were stained with
periodic acid-Schiff (PAS) reagent. For allergy, mice received an
i.p. and s.c. injection of 100 mg of A. fumigatus culture filtrate
extract (CCFA) dissolved in incomplete Freund’s adjuvant (Sigma)
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followed by two consecutive intranasal injections (a week apart) of
20 mg CCFA. A week after the last intranasal challenge, mice
received 107 Aspergillus resting conidia and evaluated a week later
(16424201). GAG (250 mg/kg i.n.) or vehicle alone was
administered daily, for a week, in concomitance with the Aspergillus
infection.
Collection of broncho-alveolar lavage (BAL) fluid
Lungs were filled thoroughly with 1 ml aliquots of pyrogen-free
saline through a 22-gauge bead-tipped feeding needle introduced
into the trachea. The lavage fluid was collected in a plastic tube on
ice and centrifuged at 400 g, 4uC, for 5 min. For differential BAL
cell counts, cytospin preparations were made and stained with
May- Gru¨nwald Giemsa reagents (Sigma-Aldrich). At least 200
cells per cytospin preparation were counted and the absolute
number of each cell type was calculated. Photographs were
observed using a BX51 microscope (Olympus, Milan, Italy) and
images were captured using a high-resolution DP71 camera
(Olympus).
Dextran sulfate sodium–induced colitis
Mice received either regular drinking water (control) or 2.5%
dextran sulfate sodium (DSS) in drinking water for 7 days and then
allowed to recover by drinking water alone for an additional 7
days. GAG was given intraperitoneally (1 mg/kg) daily for a week.
Weight changes were recorded daily, and the day after the 7-days
of rest mice were killed and tissues were collected for histology and
cytokine analysis. Colonic sections were stained with H&E [32].
To assess colitis severity, stool and histological scores were used
that recently were introduced and proven sensitive to experimental
therapy [33].
Cell purification and cell cultures
Purified peritoneal CD11b+ Gr-1+ polymorphonuclear neutro-
phils (PMNs) (.98% pure on FACS analysis) were obtained as
described [34]. Lung epithelial cells were isolated as described [35]
Murine macrophages were isolated from total lung cells after
2 hours plastic adherence at 37uC. PMNs, epithelial cells and
macrophages were exposed to unopsonized Aspergillus conidia at
the ratio of 1:1 or LPS (10 ng/ml) at 37uC for 1 hour in the
presence of different concentrations (1 or 20 mg/ml) of GAG for
18 hours before the assessment of Il1ra mRNA expression.
Statistical analysis
The differences between the various stimulations were analyzed
with the Wilcoxon signed rank test (p-value of ,0.05 was
considered statistically significant). All experiments were per-
formed at least twice and data represent cumulative results of all
experiments performed and are presented as mean +/2 standard
error of the mean (SEM) unless otherwise indicated. Data was
analyzed using GraphPad Prism v5.0.
Author Contributions
Conceived and designed the experiments: LABJ CAD MGN JPL LR
FLvdV. Performed the experiments: MSG SB TF ADL SM KLB.
Analyzed the data: MSG CAD MGN LR JPL FLvdV. Contributed
reagents/materials/analysis tools: LABJ SAR WBvdB CAD TF. Wrote the
paper: MSG MGN LR JPL FLvdV.
References
1. Chai LY, Hsu LY (2011) Recent advances in invasive pulmonary aspergillosis.
Curr Opin Pulm Med 17: 160–166.
2. Romani L (2011) Immunity to fungal infections. Nat Rev Immunol 11: 275–288.
3. Chai LY, Netea MG, Vonk AG, Kullberg BJ (2009) Fungal strategies for
overcoming host innate immune response. Med Mycol 47: 227–236.
4. Aimanianda V, Bayry J, Bozza S, Kniemeyer O, Perruccio K, et al. (2009)
Surface hydrophobin prevents immune recognition of airborne fungal spores.
Nature 460: 1117–1121.
5. Chai LY, Netea MG, Sugui J, Vonk AG, van de Sande WW, et al. (2010)
Aspergillus fumigatus conidial melanin modulates host cytokine response.
Immunobiology 215: 915–920.
6. Chai LY, Kullberg BJ, Vonk AG, Warris A, Cambi A, et al. (2009) Modulation
of Toll-like receptor 2 (TLR2) and TLR4 responses by Aspergillus fumigatus.
Infect Immun 77: 2184–2192.
7. Fontaine T, Delangle A, Simenel C, Coddeville B, van Vliet SJ, et al. (2011)
Galactosaminogalactan, a new immunosuppressive polysaccharide of Aspergillus
fumigatus. PLoS Pathog 7: e1002372.
8. Loussert C, Schmitt C, Prevost MC, Balloy V, Fadel E, et al. (2010) In vivo
biofilm composition of Aspergillus fumigatus. Cell Microbiol 12: 405–410.
9. Gravelat FN, Beauvais A, Liu H, Lee MJ, Snarr BD, et al. (2013) Aspergillus
Galactosaminogalactan Mediates Adherence to Host Constituents and Conceals
Hyphal beta-Glucan from the Immune System. PLoS Pathog 9: e1003575.
10. Sheppard DC (2011) Molecular mechanism of Aspergillus fumigatus adherence
to host constituents. Curr Opin Microbiol 14: 375–379.
11. Guo L, Wei G, Zhu J, Liao W, Leonard WJ, et al. (2009) IL-1 family members
and STAT activators induce cytokine production by Th2, Th17, and Th1 cells.
Proc Natl Acad Sci U S A 106: 13463–13468.
12. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, et al. (2009) IL-1
acts directly on CD4 T cells to enhance their antigen-driven expansion and
differentiation. Proc Natl Acad Sci U S A 106: 7119–7124.
13. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of
inflammatory diseases. Blood 117: 3720–3732.
14. van de Veerdonk FL, Netea MG, Dinarello CA, van der Meer JW (2011)
Anakinra for the inflammatory complications of chronic granulomatous disease.
Neth J Med 69: 95.
15. Groux H, O9Garra A, Bigler M, Rouleau M, Antonenko S, et al. (1997) A CD4+
T-cell subset inhibits antigen-specific T-cell responses and prevents colitis.
Nature 389: 737–742.
16. Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B (2011) IL-10 and IL-
10 receptor defects in humans. Ann N Y Acad Sci 1246: 102–107.
17. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA (2011)
Inflammasome activation and IL-1beta and IL-18 processing during infection.
Trends Immunol 32: 110–116.
18. Sainz J, Perez E, Gomez-Lopera S, Jurado M (2008) IL1 gene cluster
polymorphisms and its haplotypes may predict the risk to develop invasive
pulmonary aspergillosis and modulate C-reactive protein level. J Clin Immunol
28: 473–485.
19. Werner JL, Metz AE, Horn D, Schoeb TR, Hewitt MM, et al. (2009) Requisite
role for the dectin-1 beta-glucan receptor in pulmonary defense against
Aspergillus fumigatus. J Immunol 182: 4938–4946.
20. Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002) Invasive
aspergillosis in allogeneic stem cell transplant recipients: changes in epidemi-
ology and risk factors. Blood 100: 4358–4366.
21. Schaffner A, Douglas H, Braude A (1982) Selective protection against conidia by
mononuclear and against mycelia by polymorphonuclear phagocytes in
resistance to Aspergillus. Observations on these two lines of defense in vivo
and in vitro with human and mouse phagocytes. J Clin Invest 69: 617–631.
22. Koenders MI, Devesa I, Marijnissen RJ, Abdollahi-Roodsaz S, Boots AM, et al.
(2008) Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in
interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 58: 3461–
3470.
23. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, et al. (2009) An
autoinflammatory disease with deficiency of the interleukin-1-receptor antago-
nist. N Engl J Med 360: 2426–2437.
24. Lilly LM, Gessner MA, Dunaway CW, Metz AE, Schwiebert L, et al. (2012) The
beta-Glucan Receptor Dectin-1 Promotes Lung Immunopathology during
Fungal Allergy via IL-22. J Immunol 189(7):3653–60.
25. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by
blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:
633–652.
26. Chai LY, van de Veerdonk F, Marijnissen RJ, Cheng SC, Khoo AL, et al. (2010)
Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than
type 17 T helper (Th17), cellular immunity. Immunology 130: 46–54.
27. Netea MG, Warris A, Van der Meer JW, Fenton MJ, Verver-Janssen TJ, et al.
(2003) Aspergillus fumigatus evades immune recognition during germination
through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis 188:
320–326.
28. van de Veerdonk FL, Marijnissen RJ, Kullberg BJ, Koenen HJ, Cheng SC, et al.
(2009) The macrophage mannose receptor induces IL-17 in response to Candida
albicans. Cell Host Microbe 5: 329–340.
GAG of Aspergillus fumigatus Induces IL-1Ra
PLOS Pathogens | www.plospathogens.org 9 March 2014 | Volume 10 | Issue 3 | e1003936
29. Gearing AJ, Bird CR, Bristow A, Poole S, Thorpe R (1987) A simple sensitive
bioassay for interleukin-1 which is unresponsive to 10(3) U/ml of interleukin-2.
J Immunol Methods 99: 7–11.
30. Bonifazi P, D9Angelo C, Zagarella S, Zelante T, Bozza S, et al. (2010)
Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory
pathways protects from aspergillosis. Mucosal Immunol 3: 193–205.
31. Bozza S, Perruccio K, Montagnoli C, Gaziano R, Bellocchio S, et al. (2003) A
dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic
transplantation. Blood 102: 3807–3814.
32. Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, et al. (2008)
TL1A (TNFSF15) regulates the development of chronic colitis by modulating
both T-helper 1 and T-helper 17 activation. Gastroenterology 135: 552–567.
33. Engel MA, Leffler A, Niedermirtl F, Babes A, Zimmermann K, et al. (2011)
TRPA1 and substance P mediate colitis in mice. Gastroenterology 141: 1346–
1358.
34. Bellocchio S, Moretti S, Perruccio K, Fallarino F, Bozza S, et al. (2004) TLRs
govern neutrophil activity in aspergillosis. J Immunol 173: 7406–7415.
35. You Y, Richer EJ, Huang T, Brody SL (2002) Growth and differentiation of
mouse tracheal epithelial cells: selection of a proliferative population.
Am J Physiol Lung Cell Mol Physiol 283: L1315–1321.
GAG of Aspergillus fumigatus Induces IL-1Ra
PLOS Pathogens | www.plospathogens.org 10 March 2014 | Volume 10 | Issue 3 | e1003936
